MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Kodu・Aktsiate loetelu・VolitionRX Ltd

VolitionRX Ltd

Suletud

0.33 3.13

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.3

Max

0.34

Põhinäitajad
By Trading Economics
Sissetulek	936K -5.4M
Müük	221K 627K
Kasumimarginaal	-857.414
Töötajad	75
EBITDA	1.3M -4.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+542.86% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-12M 34M
Eelmine avamishind	-2.8
Eelmine sulgemishind	0.33

VolitionRX Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. jaan 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. jaan 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. jaan 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. jaan 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. jaan 2026, 20:54 UTC

Tulu

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. jaan 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. jaan 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. jaan 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. jaan 2026, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. jaan 2026, 19:22 UTC

Omandamised, ülevõtmised, äriostud

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. jaan 2026, 18:21 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. jaan 2026, 18:20 UTC

Omandamised, ülevõtmised, äriostud

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. jaan 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. jaan 2026, 18:16 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. jaan 2026, 18:01 UTC

Omandamised, ülevõtmised, äriostud

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. jaan 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Võrdlus sarnastega

Hinnamuutus

VolitionRX Ltd Prognoos

Hinnasiht

By TipRanks

542.86% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 542.86%

Kõrge 3 USD

Madal 1.5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi VolitionRX Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi VolitionRX Ltd aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.